

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: KE, Zhaoxi

Art Unit:

Serial No.: Not yet assigned

Examiner:

Filed: April 20, 2004

Atty. Docket: CL001313-DIV

For: ISOLATED HUMAN KINASE PROTEINS, NUCLEIC
ACID MOLECULES ENCODING HUMAN KINASE
PROTEINS, AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

No fee is due for this submission. However, the Patent and Trademark Office is authorized to charge any necessary fees related to the processing of this application to Deposit Account No. 50-0970.

Respectfully submitted,

CELERA GENOMICS

Date: April 20, 2004

By: 

Justin D. Karjala, Reg No. 43,704

Celera Genomics Corporation
45 West Gude Drive, C2-4#21
Rockville, MD 20850
Tel: 240-453-3812
Fax: 240-453-3084

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not yet assigned
				Filing Date	April 20, 2004
				First Named Inventor	Zhaoxi KE
				Art Unit	
				Examiner Name	
				Attorney Docket Number	CL001313-DIV
Sheet	1	of	2		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials ³	Cite No. ¹	Foreign Patent Document ² Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 98 11234	3/19/1998	Incyte Pharmaceuticals Inc.		
		EP 0 887 081 A2	12/30/1998	SmithKline Beecham Corp.		
		EP 0 861 896 A2	09/02/1998	Dade Behring Marburg GmbH		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Bureau Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	Not yet assigned
		Filing Date	April 20, 2004
		First Named Inventor	Zhaoxi KE
		Group Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	CL001313-DIV

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW90139, KUMAN JM, March 1999.	
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW77217, LANG et al., November 1998.	
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAB2115, YU et al., January 2001.	
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAB65613, PLOWMAN et al., March 2001.	
		Database GenBank, US National Library of Medicine, (Bethesda, MD, USA) No. AAW52025, AU-YOUNG et al., March 2001.	
		EP 0 887081 A2 (SMITHKLINE BEECHAM CORP) 30 December 1998 (30.12.1998) see entire document.	
		EP 0 861896-A2 (DADE BEHRING MARBUG GMBH) 02 September 1998 (02.09.1998) see entire document.	
		WO 98/11234-A2 (INCYTE PHARM INC.) 19 March 1998 (19.03.1998) see entire document.	
		International Search Report dated January 15, 2004.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.